Capital International Investors Acquires 79,810 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Capital International Investors increased its position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) by 12.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 718,038 shares of the medical device company's stock after buying an additional 79,810 shares during the quarter. Capital International Investors owned 1.09% of Tandem Diabetes Care worth $25,864,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently modified their holdings of the business. Stifel Financial Corp lifted its holdings in Tandem Diabetes Care by 6.8% in the third quarter. Stifel Financial Corp now owns 34,072 shares of the medical device company's stock valued at $1,445,000 after buying an additional 2,160 shares during the period. Geode Capital Management LLC increased its holdings in Tandem Diabetes Care by 1.2% during the 3rd quarter. Geode Capital Management LLC now owns 1,525,816 shares of the medical device company's stock worth $64,722,000 after purchasing an additional 18,187 shares in the last quarter. McIlrath & Eck LLC purchased a new stake in Tandem Diabetes Care in the 3rd quarter valued at $52,000. Franklin Resources Inc. lifted its position in shares of Tandem Diabetes Care by 95.6% during the third quarter. Franklin Resources Inc. now owns 26,785 shares of the medical device company's stock valued at $1,136,000 after purchasing an additional 13,088 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its stake in shares of Tandem Diabetes Care by 134.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 197,583 shares of the medical device company's stock worth $8,379,000 after buying an additional 113,355 shares during the last quarter.

Tandem Diabetes Care Trading Up 6.6 %

Shares of NASDAQ:TNDM traded up $1.10 on Thursday, hitting $17.67. The company had a trading volume of 1,357,116 shares, compared to its average volume of 1,503,663. Tandem Diabetes Care, Inc. has a 1 year low of $15.75 and a 1 year high of $53.69. The firm has a market capitalization of $1.18 billion, a price-to-earnings ratio of -9.16 and a beta of 1.52. The firm's 50-day simple moving average is $20.78 and its two-hundred day simple moving average is $29.60. The company has a quick ratio of 2.32, a current ratio of 2.90 and a debt-to-equity ratio of 1.29.

Analyst Ratings Changes

A number of analysts recently issued reports on TNDM shares. Morgan Stanley downgraded shares of Tandem Diabetes Care from an "overweight" rating to an "equal weight" rating and decreased their price objective for the stock from $45.00 to $22.00 in a report on Wednesday, March 5th. Wells Fargo & Company reiterated an "equal weight" rating and set a $22.00 price target (down from $38.00) on shares of Tandem Diabetes Care in a research report on Monday, March 3rd. Citigroup downgraded Tandem Diabetes Care from a "buy" rating to a "neutral" rating and lowered their price objective for the stock from $35.00 to $24.00 in a research report on Tuesday, March 4th. Royal Bank of Canada dropped their target price on shares of Tandem Diabetes Care from $65.00 to $55.00 and set an "outperform" rating for the company in a research report on Thursday, February 27th. Finally, Sanford C. Bernstein lowered Tandem Diabetes Care from an "outperform" rating to a "market perform" rating and reduced their price objective for the company from $35.00 to $25.00 in a research report on Friday, February 28th. Eight investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $43.88.

Insiders Place Their Bets

In other Tandem Diabetes Care news, COO Jean-Claude Kyrillos bought 10,538 shares of the stock in a transaction dated Friday, March 7th. The stock was purchased at an average cost of $18.12 per share, for a total transaction of $190,948.56. Following the completion of the acquisition, the chief operating officer now owns 10,538 shares of the company's stock, valued at approximately $190,948.56. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 2.20% of the company's stock.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.